Average number of CD11b+Annexin V+ cells among BMCs of AML patients (AML-1, AML-2, and AML-4) following 100 μM radotinib treatment was 3.2-fold higher than in the control group at 72 h. The gene discussed is ANXA5; the disease is acute myeloid leukemia.